SEGMENT INFORMATION

3 Months Ended

Mar. 31, 2016

SEGMENT INFORMATION [Abstract]

SEGMENT INFORMATION

NOTE 4. SEGMENT INFORMATION

We operate in one business segment: the research, development and commercialization of pharmaceutical products.  Our corporate headquarters in the United States collects product sales, licensing fees, and royalties from our arrangements with external customers and licensees.  Our entire business is managed by a single management team, which reports to the Chief Executive Officer.

Our product revenues are currently derived primarily from the sale of Altrazeal® in sixteen international markets and from our sales activities in the United States.

Revenues per geographic area for the three months ended March 31 are summarized as follows:

Revenues		2016	%	2015	%
	Domestic	$      7,516	7%	$      6,802	2%
	International	101,276	93%	287,846	98%
	Total	$  108,792	100%	$  294,648	100%

A significant portion of our revenues are derived from a few major customers.  Customers with greater than 10% of total revenues for the three months ended March 31 are represented on the following table:

Customers		Product	2016	2015
	Customer A	Altrazeal®	87%	1%
	Customer B	Altrazeal®	---	93%
	Total		87%	94%